PITU is designed to temporarily isolate and transport patients with confirmed or suspected COVID-19 infection.
Arrowhead Medical Center Head of Anesthesiology, Dr. Mark Comunale, worked on developing the unit in 2015 after the outbreak of Ebola. AR Tech joined Dr. Comunale's efforts two years ago.
Currently, PITU is ready for use with FDA Emergency Use Authorization on the frontline in the battle against the novel Coronavirus.
PITU protects medical professionals, patients, and visiting family members against respiratory droplets and infection by using a negative pressure enclosure which surrounds the patient.
Patients can be treated by medical staff, and family members who are properly attired can even visit those patients.
A and R Tarpaulins Inc. is the parent company of AR Tech and AR Industries and provides products and services for medical companies, flight hardware, and ground support to various aerospace companies providing satellite launches.
A and R Tarpaulins also provides architectural products and services for homes and businesses, and industrial products for the transportation industry.
Lupin's Brivaracetam Oral Solution approved by US FDA
Johnson & Johnson submits sBLA to FDA for first-ever treatment for wAIHA
AlzeCure's ACD440 granted EU orphan drug status for erythromelalgia
Armata Pharmaceuticals' AP-SA02 receives QIDP designation from US FDA
Immedica Pharma's Loargys (pegzilarginase-nbln) receives accelerated US FDA approval
Gossamer Bio reports topline Phase 3 PROSERA results for seralutinib in PAH
Organon licenses MIUDELLA IUD from Sebela Pharmaceuticals
Gilead to acquire Arcellx to gain full control of anito-cel
Novo Nordisk's CagriSema achieves 23% weight loss but misses primary endpoint in REDEFINE 4 trial
AbbVie's VENCLEXTA (venetoclax) and acalabrutinib combination receives US FDA approval to treat CLL
Vanda Pharmaceuticals' BYSANTI (milsaperidone) tablets receive US FDA approval
FDA approves Genentech oral Venclexta plus AstraZeneca's Calquence combination for first-line CLL
EMA validates Enhertu application for post-neoadjuvant HER2-positive early breast cancer
Merck reports positive Phase 3 data for Enflonsia in high-risk children across two RSV seasons